Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Tuesday, October 27, 2026

⚡ Executive Takeaway

The weekend's data met the tape Monday, and the tape paid almost no one. Amgen, holding the cleanest new standard of the congress, earned barely half a point over the sector. Merck walked in with an overall survival win and a priority review already dated, and still cleared lower by more than the sector rose. Here is the part nobody prints: Monday was the heaviest single day of franchise defense this cycle, five large sponsors presenting oncology wins into one session, and attention is a clearing price too. When everything on the tape is a winner, the marginal buyer is exhausted, and the discount shows up as indifference rather than punishment. So the through line survives its first grade, narrowed: a new standard gets paid only net of the franchise it has to replace, and Merck carries the biggest franchise in oncology. One session is not a verdict, and we will not pretend otherwise. Friday's close grades the week.

The TroFuse-005 table, the full scoreboard, the race figures, and the filings, all below. 👉 Read Full Analysis

🧪 The Successor's First Verdict

Merck's designated Keytruda successor cut the risk of death 32 percent in its first global Phase 3 survival win, and the FDA decision is already dated: June 15, 2027. MRK

TroFuse-005 enrolled 776 patients with advanced or recurrent endometrial cancer already treated with platinum chemotherapy and a PD-1 or PD-L1 inhibitor, a population whose standard of care is single agent chemotherapy from another era. Sacituzumab tirumotecan, the TROP2 directed antibody drug conjugate Merck licensed from China's Kelun, beat physician's choice of doxorubicin or paclitaxel on both primary endpoints at the interim analysis, presented Monday in a presidential symposium in Madrid and published in The Lancet. Merck calls this the first Phase 3 of a TROP2 directed ADC in this setting, is running 18 global Phase 3 trials of the molecule, and said it is hopeful for an approval before the June 15, 2027 action date, per the release. The trade is not free: grade 3 or higher treatment related events ran 13 points above the control arm, though discontinuations were lower on the ADC. The market's first verdict was colder, in the scoreboard below. The numbers:

📊 The ESMO Scoreboard

Five franchises defended data at once Monday, and the market paid only the new standard, barely. AMGN | MRK | SMMT | RHHBY | MRNA

All closes are exchange settled, all percentages ours, and every session below is the first reaction to data presented over the ESMO weekend, labeled as such. Amgen closed at 444.63, up 1.2 percent, the only gainer among the weekend's five big presenters, on a day the XBI rose 0.6 percent and the S&P rose 0.7. Merck closed at 140.61, down 3.2 percent, holding an overall survival win and a dated priority review; no company disclosure beyond the data and its investor event assigns the move. Summit closed at 14.50, down 6.3 percent, in the first session after HARMONi-GI1's biliary tract win over durvalumab, a China run trial whose US registration study only activates this quarter. Roche's ADR closed at 59.98, down 1.9 percent, labeled as an ADR print. Moderna, in its third session since the leak week, closed at 198.85, down 0.6 percent. AstraZeneca, carrying both a win and a primary endpoint miss out of the weekend, closed at 172.06, up 0.3 percent, a wash.

🧬 The ADC and RAS Races

Bristol Myers says its bispecific ADC is five for five in Phase 3, and Incyte put up an 81 percent response rate in first line pancreatic cancer. BMY | INCY

Every figure in this item comes from ESMO presentations as reported by Fierce, not from company releases, and stays out of our headlines accordingly. Iza-bren, the EGFR and HER3 bispecific ADC Bristol Myers licensed from SystImmune, cut the risk of progression 60 percent after EGFR TKI failure in NSCLC in Panku-Lung01 (median PFS 11.1 versus 5.7 months, response rate 60.2 versus 34.5 percent) and posted 8.2 versus 4.0 months in heavily pretreated HR+/HER2− breast cancer in Panku-Breast01. Chief medical officer Cristian Massacesi told Fierce the count is now five positive Phase 3 trials from five. The catch is the one that matters for a US filing: overall survival is immature in both, and Fierce notes the FDA has told Summit that significant survival is the bar in exactly this kind of setting; Bristol's own global trials read from 2028. In the KRAS G12D race, Incyte's INCB161734 with modified FOLFIRINOX posted a confirmed 81 percent response rate in 28 first line pancreatic cancer patients, Incyte's Pablo Cagnoni said in a Fierce interview, against the 82 percent RevMed's zoldonrasib posted earlier this year. His words: neck and neck. Incyte's global Phase 3 is enrolling, topline expected 2028.

🤖 AI Files for the Lab

Anthropic's IPO filing says the AI company wants to make drugs, not just sell software to the people who do. Private

Anthropic filed its S-1 Monday to list on Nasdaq as ANT, and the life sciences section reads less like a vendor's than a developer's, per Fierce Biotech's read of the filing (we could not retrieve the document itself tonight, so every claim here is attributed). The company discloses it is building its own molecular biology lab, investing toward research that could eventually produce drug candidates, and standing up a hardware standard that lets AI agents operate liquid handlers, microscopes and robotic arms. It names Novo Nordisk and Bristol Myers Squibb as pharma partners, seated Novartis chief executive Vas Narasimhan on its board in April, and paid 15.4 million shares for the computational biology startup Coefficient Bio. The risk factors read like a biotech's: biosafety, FDA oversight, and model errors contributing to patient harm. An August New York Times report put the potential raise above $100 billion. Disclosure: BioMed Nexus drafts are produced with Anthropic's Claude; we report the filing with attribution and take no view on the offering. The quieter story in the same vertical: Boehringer Ingelheim and Microsoft will explore digital patient twins for trial design, including synthetic control arms that could shrink control groups, starting in lung disease; Boehringer calls it exploratory and says any application needs validation and regulatory acceptance.

💰 Capital Markets

Windward Bio filed for a Nasdaq IPO with ten late stage readouts promised through 2029, while last week's hottest debut gave back a little more. WWB | LYCA | ZLAB

Windward Bio's F-1, filed Thursday and surfaced in Monday's coverage, puts the Swiss respiratory company on file as WWB: lead asset WIN378, an ultra long acting antibody against TSLP, is in the Phase 2/3 POLARIS-1 program in severe asthma with Phase 3 toplines expected in the first half of 2029, a COPD topline in the second half of 2027, and a TSLP and IL-13 bispecific behind it. The company held $207.3 million in cash at June 30 against up to $365 million raised to date from OrbiMed, Novo Holdings and SR One, and left the raise size blank, per the filing. It files into a cohort still being graded: Lycia's second session closed at 28.85, down 3.8 percent, still 60.3 percent above its $18.00 offer, our arithmetic. Zai Lab closed at 24.34, up 1.3 percent, with its placement expected to close on or about today and no closing release found in our Monday night checks. Disc Medicine's closing release is now four days past the expected close, with only a June 2023 lookalike surfacing in tonight's searches, a vintage trap caught rather than printed.

🧾 The Deal Tape, Caught Up

Gilead paid $1.275 billion cash for an oral IL-23 blocker still in Phase 1, and Roche rented a next generation shot at Imdelltra's target, both announced late last week. GILD | RHHBY | ZYME

Two deals crossed Thursday and Friday that our weekend sweep missed, printed here dated. Gilead agreed to acquire PepStar Therapeutics' oral IL-23R inhibitor program, led by HCXT-2001, an extended half life macrocyclic peptide in Phase 1 aimed at inflammatory bowel disease, for $1.275 billion in cash at closing, milestones undisclosed and closing expected this quarter, per Gilead's release, which also flagged a roughly $0.79 to $0.83 hit to fourth quarter earnings per share. The strategic read is the price: more than a billion dollars, upfront, for a Phase 1 oral peptide says the oral IL-23 lane is being valued like a late stage asset class. Roche took exclusive global rights to Zymeworks' ZW209, a DLL3 directed trispecific T cell engager with built in CD28 costimulation, for $55 million upfront, $40 million at the Phase 1b start, and up to $718 million in milestones, about $813 million all in by our arithmetic, plus tiered royalties, per Zymeworks' release. DLL3 is the target Amgen's Imdelltra just rewrote first line small cell lung cancer with on Saturday; Roche is buying a next generation shot at the same biology.

📋 Quick Hits

👀 What To Watch Today

📖 In Today's Full Analysis

Be sure to read the full article for all the details, including:

👉 Read the full breakdown →